Currently, lapatinib is FDA-approved for breast cancer treatment in combination with letrozole or capecitabine in hormone receptor positive and HER2+ breast cancer, or with capecitabine or with trastuzumab for receptor positive and HER2+ postmenopausal patients, in which case an increase in PFS was observed but no benefit in overall survival [153]. Here, ERBB2 is linked to breast cancer.